Skip to main content
SK Bioscience Co.,Ltd logo

SK Bioscience Co.,Ltd — Investor Relations & Filings

Ticker · 302440 ISIN · KR7302440003 KO Manufacturing
Open in API
Filings indexed 383 across all filing types
Latest filing 2023-06-19 Regulatory Filings
Country KR South Korea
Listing KO 302440

About SK Bioscience Co.,Ltd

https://www.skbioscience.com/

SK Bioscience is a biopharmaceutical company focused on the research, development, manufacturing, and commercialization of vaccines and biological products. Spun off from SK Chemicals in 2018, the company develops its own pipeline of vaccines, including cell-culture-based influenza vaccines and a COVID-19 vaccine, utilizing its established R&D and production platforms. In addition to its proprietary products, SK Bioscience provides global Contract Development and Manufacturing Organization (CDMO) services, offering end-to-end support from process development to large-scale commercial manufacturing for international partners. The company is dedicated to promoting public health by providing innovative preventative solutions to address global health challenges.

Recent filings

Filing Released Lang Actions
투자판단관련주요경영사항(COVID-19 백신 스카이코비원 세계보건기구(WHO) 긴급사용목록(Emergency Use Listing) 등재)
Regulatory Filings Classification · 1% confidence The document is a regulatory filing from SK Bioscience regarding the WHO Emergency Use Listing (EUL) for their COVID-19 vaccine, 'SKYCovione'. It is a specific corporate announcement regarding a material business event (regulatory approval/listing). Since it does not fit into specific categories like financial reports, dividends, or director dealings, and is a formal regulatory disclosure filed with the exchange, it falls under the 'Regulatory Filings' category.
2023-06-19 Korean
불성실공시법인지정예고
Regulatory Filings Classification · 1% confidence The document is a formal notice from the Korea Exchange (KRX) regarding the 'pre-designation of an unfaithful disclosure corporation' (불성실공시법인지정예고) for SK Bioscience. This relates to a regulatory action concerning a delay in disclosure. Since it pertains to regulatory compliance and legal/administrative status rather than financial results, M&A, or governance, it falls under the 'Regulatory Filings' category as a fallback for specific regulatory notices.
2023-06-15 Korean
단일판매ㆍ공급계약체결
Regulatory Filings Classification · 1% confidence The document is a formal regulatory disclosure from SK Bioscience regarding a 'Single Sales/Supply Contract' (단일판매ㆍ공급계약체결) with the Public Procurement Service of South Korea. This is a standard material event disclosure required by stock exchange regulations for significant contracts. Since it does not fit into specific categories like M&A, dividends, or director dealings, and is a formal regulatory announcement of a business event, it falls under the 'Regulatory Filings' category.
2023-06-14 Korean
기업지배구조보고서공시
Governance Information Classification · 1% confidence The document is a short announcement (965 characters) titled 'Corporate Governance Report Disclosure' which explicitly states that the detailed report is attached ('상세한 내용은 첨부된... 참조하시기 바랍니다'). According to the 'Menu vs Meal' rule, an announcement stating that a report is attached should be classified as a Report Publication Announcement (RPA).
2023-05-31 Korean
대규모기업집단현황공시[연1회공시및1/4분기용(개별회사)]
Major Shareholding Notification Classification · 1% confidence The document is a 'Corporate Group Status Disclosure' (기업집단현황공시) for SK Bioscience, which is a mandatory regulatory filing in South Korea for large business groups. It contains detailed information on company structure, financial status, board operations, shareholding, and inter-company transactions. As it is a formal regulatory disclosure required by the Korea Fair Trade Commission and does not fit into specific categories like 10-K or Earnings Release, it is classified as a Regulatory Filing (RNS).
2023-05-31 Korean
투자판단관련주요경영사항
Regulatory Filings Classification · 1% confidence The document is a regulatory filing from SK Bioscience regarding the approval of their COVID-19 vaccine (SKYCovion) by the UK MHRA. It is a 'Major Management Matter' (투자판단 관련 주요경영사항) filing, which is a standard regulatory disclosure in the Korean market (KRX). Since it does not fit into specific categories like financial reports, dividends, or M&A, it falls under the general regulatory filing category.
2023-05-30 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.